Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Typ-2-Diabetes und Adipositas Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende

Die Highlights vom Kongress des American College of Cardiology 2024

Im April diskutierten die Herz-Kreislauf-Spezialisten aus der ganzen Welt auf dem  Kongress des American College of Cardiology (ACC) u.a. neue Therapieansätze bei akutem Myokardinfarkt, koronarer Herzerkrankung, kardiogenem Schock oder Aortenklappenstenose. In unserem Kongress-Dossier haben wir für Sie Berichte über die „Late-Breaking Trials“ und andere wichtige Studien zusammengestellt. 
Erweiterte Suche
Anmelden
nach oben
Clinical Research in Cardiology
Erschienen in: Clinical Research in Cardiology 5/2008

01.05.2008 | ORIGINAL PAPER

Proinflammatory cytokines in acute myocardial infarction with and without cardiogenic shock

verfasst von: Marianne Debrunner, MD, Ernst Schuiki, MD, Elisabeth Minder, MD, Edwin Straumann, MD, Barbara Naegeli, MD, Raymond Mury, MD, Osmund Bertel, MD, Jürgen Frielingsdorf, MD

Erschienen in: Clinical Research in Cardiology | Ausgabe 5/2008

Einloggen, um Zugang zu erhalten

Abstract

Background

Inflammatory response is an important feature of acute coronary syndromes and myocardial infarction (MI). The prognostic value of proinflammatory cytokines in patients with acute MI complicated by cardiogenic shock is unknown.

Methods and results

In 41 patients admitted with acute MI (age 60 ± 11 years, six females, 19 Killip class IV) serial plasma concentration of tumor necrosis factor alpha (TNF-α), interleukin 6 (IL-6) and interleukin 1 receptor antagonist (IL-1Ra) were measured. Seven patients with cardiogenic shock (CS) developed a systemic inflammatory response syndrome (SIRS). Patients with CS—particularly those who developed SIRS—showed significantly higher cytokine levels than patients with uncomplicated MI. In patients with CS and SIRS peak levels of IL-1Ra were 223,973 pg/ml, IL-6 252.8 pg/ml and TNF-α 7.0 pg/ml. In CS without SIRS IL-1Ra levels were 19,988 pg/ml, IL-6 109.3 pg/ml and TNF-α 3.8 pg/ml. In uncomplicated MI peak IL-1Ra levels were 1,088 pg/ml, IL-6 34.1 pg/ml and TNF-α 2.6 pg/ml.

Conclusions

The inflammation-associated cytokines TNF-α, IL-6 and IL-1Ra are significantly elevated in patients with MI complicated by CS when compared to patients with uncomplicated MI. Among shock-patients IL-1Ra levels are promising diagnostic markers for early identification of patients developing SIRS, heralding a poor outcome.
Literatur
1.
Akira S, Hirano T, Taga T et al. (1990) Biology of multifunctional cytokines: IL 6 and related molecules (IL 1 and TNF). FASEB J 4:2860–2867PubMed
2.
Arai KI, Lee F, Miyajima A et al. (1990) Cytokines: coordinators of immune and inflammatory responses. Annu Rev Biochem 59:783–836PubMedCrossRef
3.
Biasucci LM (1996) Elevated Levels of Interleukin-6 in Unstable Angina. Circulation 94:874–877PubMed
4.
Biasucci LM, Liuzzo G, Fantuzzi G et al. (1999) Increasing levels of interleukin (IL)-1Ra and IL-6 during the first 2 days of hospitalization in unstable angina are associated with increased risk of in-hospital coronary events. Circulation 99:2079–2084PubMed
5.
Cannon JG, Tompkins RG, Gelfand JA et al. (1990) Circulating interleukin-1 and tumor necrosis factor in septic shock and experimental endotoxin fever. J Infect Dis 161:79–84PubMed
6.
Casey LC, Balk RA, Bone RC (1993) Plasma cytokine and endotoxin levels correlate with survival in patients with the sepsis syndrome. Ann Int Med 119:771–778PubMed
7.
8.
Fischer E, Van Zee KJ, Marano MA et al. (1992) Interleukin-1 receptor antagonist circulates in experimental inflammation and in human disease. Blood 79:2196–2200PubMed
9.
Gabay C (2002) Cytokine inhibitors in the treatment of rheumatoid arthritis. Expert Opin Biol Ther 2:135–149PubMedCrossRef
10.
Garces K (2001) Anakinra: interleukin-1 receptor antagonist therapy for rheumatoid arthritis. Issues Emerg Health Technol 1–4
11.
Ghezzi P, Dinarello CA, Bianchi M et al. (1991) Hypoxia increases production of interleukin-1 and tumor necrosis factor by human mononuclear cells. Cytokine 3:189–194PubMedCrossRef
12.
Granowitz EV, Santos AA, Poutsiaka DD et al. (1991) Production of interleukin-1-receptor antagonist during experimental endotoxaemia. Lancet 338:1423–1424PubMedCrossRef
13.
Hasdai D, Holmes DR Jr., Topol EJ et al. (1999) Frequency and clinical outcome of cardiogenic shock during acute myocardial infarction among patients receiving reteplase or alteplase. Results from GUSTO-III. Global Use of Strategies to Open Occluded Coronary Arteries. Eur Heart J 20:128–135PubMedCrossRef
14.
15.
Herrera-Garza EH, Stetson SJ, Cubillos-Garzon A et al. (1999) Tumor necrosis factor-alpha: a mediator of disease progression in the failing human heart. Chest 115:1170–1174PubMedCrossRef
16.
Hirschl MM, Gwechenberger M, Binder T et al. (1996) Assessment of myocardial injury by serum tumour necrosis factor alpha measurements in acute myocardial infarction. Eur Heart J 17:1852–1859PubMed
17.
Hochman JS, Sleeper LA, Webb JG et al. (1999) Early revascularization in acute myocardial infarction complicated by cardiogenic shock. SHOCK investigators. Should we emergently revascularize occluded coronaries for cardiogenic shock. N Engl J Med 341:625–634PubMedCrossRef
18.
Hochman JS, Sleeper LA, White HD et al. (2001) One-year survival following early revascularization for cardiogenic shock. JAMA 285:190–192PubMedCrossRef
19.
Kohsaka S, Menon V, Lowe AM et al. (2005) Systemic inflammatory response syndrome after acute myocardial infarction complicated by cardiogenic shock. Arch Intern Med 165:1643–1650PubMedCrossRef
20.
Levine B, Kalman J, Mayer L et al. (1990) Elevated circulating levels of tumor necrosis factor in severe chronic heart failure. N Engl J Med 323:236–241PubMed
21.
Mantovani A, Bussolino F, Dejana E (1992) Cytokine regulation of endothelial cell function. FASEB J 6:2591–2599PubMed
22.
Millar AB, Foley NM, Singer M et al. (1989) Tumour necrosis factor in bronchopulmonary secretions of patients with adult respiratory distress syndrome. Lancet 2:712–714PubMedCrossRef
23.
Moser R, Schleiffenbaum B, Groscurth P et al. (1989) Interleukin 1 and tumor necrosis factor stimulate human vascular endothelial cells to promote transendothelial neutrophil passage. J Clin Invest 83:444–455PubMedCrossRef
24.
Neumann FJ, Ott I, Gawaz M et al. (1995) Cardiac release of cytokines and inflammatory responses in acute myocardial infarction. Circulation 92:748–755PubMed
25.
Schuler J, Maier B, Behrens S et al. (2006) Present treatment of acute myocardial infarction in patients over 75 years. Clin Res Cardiol 95:360–367PubMedCrossRef
26.
Shigematsu S (1998) Therapeutic potential of interleukin-1 receptor antagonist in inflammatory bowel disease. Kurume Med J 45:175–179PubMed
27.
Sturk A, Hack CE, Aarden LA et al. (1992) Interleukin-6 release and the acute-phase reaction in patients with acute myocardial infarction: a pilot study. J Lab Clin Med 119:574–579PubMed
28.
Suffredini AF, Fromm RE, Parker MM et al. (1989) The cardiovascular response of normal humans to the administration of endotoxin. N Engl J Med 321:280–287PubMed
29.
Torre-Amione G, Kapadia S, Lee J et al. (1996) Tumor necrosis factor-alpha and tumor necrosis factor receptors in the failing human heart. Circulation 93:704–711PubMed
30.
Vaddi K (1994) Increased secretion of tumor necrosis factor-α and interferon-γ by mononuclear leukocytes in patients with ischemic heart disease. Circulation 90:694–699PubMed
31.
van der Poll T, Levi M, Hack CE et al. (1994) Elimination of interleukin 6 attenuates coagulation activation in experimental endotoxemia in chimpanzees. J Exp Med 179:1253–1259PubMedCrossRef
32.
Werra Id. (1997) Cytokines, nitrite/nitrate, soluble tumor necrosis factro receptors, and procalcitonin concentrations: compaision in patients with septic shock, cardiogenic shock, and bacterial pneumonia. Crit Care Med 25:607–613PubMedCrossRef
Metadaten
Titel
Proinflammatory cytokines in acute myocardial infarction with and without cardiogenic shock
verfasst von
Marianne Debrunner, MD
Ernst Schuiki, MD
Elisabeth Minder, MD
Edwin Straumann, MD
Barbara Naegeli, MD
Raymond Mury, MD
Osmund Bertel, MD
Jürgen Frielingsdorf, MD
Publikationsdatum
01.05.2008
Verlag
D. Steinkopff-Verlag
Erschienen in
Clinical Research in Cardiology / Ausgabe 5/2008
Print ISSN: 1861-0684
Elektronische ISSN: 1861-0692
DOI
https://doi.org/10.1007/s00392-007-0626-5

Weitere Artikel der Ausgabe 5/2008

Clinical Research in Cardiology 5/2008 Zur Ausgabe

ORIGINAL PAPER

Elevated B-type natriuretic peptide levels in patients with nonischemic cardiomyopathy predict occurrence of arrhythmic events

ORIGINAL PAPER

Stent implantation and balloon angioplasty for treatment of branch pulmonary artery stenosis in children

CLINICAL CORRESPONDENCE

Antithrombotic triple therapy in a patient with multiple thrombi, subacute myocardial infarction and coronary stent implantation

ORIGINAL PAPER

Allopurinol improves endothelial function and reduces oxidant-inflammatory enzyme of myeloperoxidase in metabolic syndrome

ORIGINAL PAPER

Revival of an old method with new techniques: balloon aortic valvuloplasty of the calcified aortic stenosis in the elderly

CLINICAL CORRESPONDENCE

Therapy effects of green tea in a patient with systemic light-chain amyloidosis

Neu im Fachgebiet Kardiologie

„Jeder Fall von plötzlichem Tod muss obduziert werden!“

17.05.2024 Plötzlicher Herztod Nachrichten

Ein signifikanter Anteil der Fälle von plötzlichem Herztod ist genetisch bedingt. Um ihre Verwandten vor diesem Schicksal zu bewahren, sollten jüngere Personen, die plötzlich unerwartet versterben, ausnahmslos einer Autopsie unterzogen werden.

Hirnblutung unter DOAK und VKA ähnlich bedrohlich

17.05.2024 Direkte orale Antikoagulanzien Nachrichten

Kommt es zu einer nichttraumatischen Hirnblutung, spielt es keine große Rolle, ob die Betroffenen zuvor direkt wirksame orale Antikoagulanzien oder Marcumar bekommen haben: Die Prognose ist ähnlich schlecht.

Schlechtere Vorhofflimmern-Prognose bei kleinem linken Ventrikel

17.05.2024 Vorhofflimmern Nachrichten

Nicht nur ein vergrößerter, sondern auch ein kleiner linker Ventrikel ist bei Vorhofflimmern mit einer erhöhten Komplikationsrate assoziiert. Der Zusammenhang besteht nach Daten aus China unabhängig von anderen Risikofaktoren.

Semaglutid bei Herzinsuffizienz: Wie erklärt sich die Wirksamkeit?

17.05.2024 Herzinsuffizienz Nachrichten

Bei adipösen Patienten mit Herzinsuffizienz des HFpEF-Phänotyps ist Semaglutid von symptomatischem Nutzen. Resultiert dieser Benefit allein aus der Gewichtsreduktion oder auch aus spezifischen Effekten auf die Herzinsuffizienz-Pathogenese? Eine neue Analyse gibt Aufschluss.

Update Kardiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise